Cesar (@cesaraperezmd) 's Twitter Profile
Cesar

@cesaraperezmd

Director of Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists, Lake Nona @SarahCannonDocs #hncsm #HeadandNeckCancer

ID: 432180094

calendar_today09-12-2011 03:55:11

16 Tweet

52 Followers

40 Following

ASCO (@asco) 's Twitter Profile Photo

#ASCO21 Press Release: JUPITER-02 Trial- Toripalimab plus standard first-line chemo significantly delayed disease progression for pts w recurrent or metastatic nasopharyngeal carcinoma fal.cn/3fQ5G #hncsm #immunoonc

#ASCO21 Press Release: JUPITER-02 Trial- Toripalimab plus standard first-line chemo significantly delayed disease progression for pts w recurrent or metastatic nasopharyngeal carcinoma fal.cn/3fQ5G #hncsm #immunoonc
OncLive.com (@onclive) 's Twitter Profile Photo

According to data from a landmark phase 3 trial, in the ITT population of patients with advanced primary SCCHN, the Multikine treatment regimen yielded an OS benefit of 14.1%. #hncsm ow.ly/HoEg50FlLAw

According to data from a landmark phase 3 trial, in the ITT population of patients with advanced primary SCCHN, the Multikine treatment regimen yielded an OS benefit of 14.1%. #hncsm ow.ly/HoEg50FlLAw
Ezra Cohen (@drezracohen) 's Twitter Profile Photo

Cabozantinib demonstrates efficacy in radioactive-iodine and VEGFR refractory patients. Another option for thyroid cancer patients but keep in mind the importance of molecular testing to find actionable alterations in NTRK, RET, and BRAF. thelancet.com/journals/lanon…

NatureRevClinOncol (@natrevclinoncol) 's Twitter Profile Photo

In the phase III JUPITER-02 trial, addition of the anti-PD-1 antibody toripalimab to first-line gemcitabine plus cisplatin for pts with advanced-stage nasopharyngeal carcinoma improved PFS 11.7 vs 8.2 months and also OS (HR 0.61, P = 0.046): nature.com/articles/s4159… #hncsm

Sarah Cannon Docs (@sarahcannondocs) 's Twitter Profile Photo

It's World Cancer Research Day and Dr. Cesar Perez, Director of Drug Development at Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, is sharing his wisdom on the importance of clinical trials in the life of patients facing cancer. #WorldCancerResearchDay

OncLive.com (@onclive) 's Twitter Profile Photo

.U.S. FDA granted a fast track designation to KIN-2787 in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma. Cesar Sarah Cannon Docs #melcsm ow.ly/S58P50LtLgL

Dr. Estela Rodriguez (@latinamd) 's Twitter Profile Photo

Si la montaña no va a Mahoma, Mahoma va a la montaña. ( If the mountain does not come to Mohammed…) Visiting our former Sylvester Comprehensive Cancer Center colleague and friend Cesar in Lake Nona, FL. FCS Foundation

Si la montaña no va a Mahoma, Mahoma va a la montaña. ( If the mountain does not come to Mohammed…) 

Visiting our former <a href="/SylvesterCancer/">Sylvester Comprehensive Cancer Center</a> colleague and friend <a href="/CesarAPerezMD/">Cesar</a> in Lake Nona, FL. <a href="/FLCancerFound/">FCS Foundation</a>
CancerNetwork® (@cancernetwrk) 's Twitter Profile Photo

The FDA has granted FTD to CRB-701, a next-generation ADC targeting nectin-4, for patients with recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy and an anti-PD(L)1 therapy. hubs.li/Q03JRtl90 #hncsm #oncology #cancer